Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Accounts Payables (2021 - 2026)

bioAffinity Technologies has reported Accounts Payables over the past 6 years, most recently at $836211.0 for Q1 2026.

  • Quarterly Accounts Payables fell 39.47% to $836211.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $836211.0 through Mar 2026, down 39.47% year-over-year, with the annual reading at $761901.0 for FY2025, 22.83% down from the prior year.
  • Accounts Payables was $836211.0 for Q1 2026 at bioAffinity Technologies, up from $761901.0 in the prior quarter.
  • Over five years, Accounts Payables peaked at $1.4 million in Q1 2025 and troughed at $146537.0 in Q1 2023.
  • The 5-year median for Accounts Payables is $782937.0 (2024), against an average of $689378.5.
  • Year-over-year, Accounts Payables skyrocketed 452.09% in 2023 and then crashed 39.47% in 2026.
  • A 5-year view of Accounts Payables shows it stood at $345042.0 in 2022, then soared by 75.28% to $604789.0 in 2023, then skyrocketed by 63.25% to $987311.0 in 2024, then decreased by 22.83% to $761901.0 in 2025, then grew by 9.75% to $836211.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Accounts Payables are $836211.0 (Q1 2026), $761901.0 (Q4 2025), and $940761.0 (Q3 2025).